FOCUS ON MEROPENEM - A BROAD-SPECTRUM PARENTERAL CARBAPENEM ANTIMICROBIAL AGENT

Meropenem is the second carbapenem antimicrobial agent to gain FDA app roval in the United States, Clinical trials have demonstrated at least equivalent efficacy of meropenem versus comparator agents, including the carbapenem imipenem/cilastatin, in a variety of infections, includ ing meningitis, and intra-abdominal, urinary, and lower respiratory tr act infections. Compared with imipenem, meropenem is associated with a lower incidence of gastrointestinal side effects and a reduced potent ial to induce seizures, These advantages will particularly benefit pat ients with increased seizure potential, such as those with meningitis or pre-existing seizure disorders.